Esperion

Quote
















anonymous said:
Yeah right . Coffee delivery and knowing clinic addresses. Your such a dumbfuck when everything is with existing relationship, understanding managed care in your territory and who are the drivers and writers. This is what was missing in 2020. Oh, and how could I forget the stupid question on how many scripts I could bring in a week. Yep those idiot RBL's fell for the reps who promised thousands of scripts per week. Anyone remember the volume the entire company was bringing in per week in April of 2020. It was pretty fucking weak. Esperion was blaming cafepharma negativity for their lack of success. Total blame shifting. Tomorrow will bring more bad news and the excuse train will continue. Maybe blame covid some more. Get a good night sleep tonight as your going to have some tossing and turning nights ahead of you.
Click to expand...
Dumb. Ass. Karen.
 
















anonymous said:
Data not impressive. No difference in death verses placebo. 20-25% reduction in LDL. High adverse events. This wasn't what they were looking for.
Click to expand...
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
More crying from the team of bitches
 




anonymous said:
Yeah right . Coffee delivery and knowing clinic addresses. Your such a dumbfuck when everything is with existing relationship, understanding managed care in your territory and who are the drivers and writers. This is what was missing in 2020. Oh, and how could I forget the stupid question on how many scripts I could bring in a week. Yep those idiot RBL's fell for the reps who promised thousands of scripts per week. Anyone remember the volume the entire company was bringing in per week in April of 2020. It was pretty fucking weak. Esperion was blaming cafepharma negativity for their lack of success. Total blame shifting. Tomorrow will bring more bad news and the excuse train will continue. Maybe blame covid some more. Get a good night sleep tonight as your going to have some tossing and turning nights ahead of you.
Click to expand...
Let’s face it, you were a bad interview then, and undoubtedly would be now.
 




Still no clinical discussion? Here's a chance to tell us why investors dumped around 15 million shares today due to the Clear Data having lackluster results. This was Esperions big weekend where they would be able to pound their chest and it didn't happen. The market reacted accordingly today.
 




anonymous said:
Still no clinical discussion? Here's a chance to tell us why investors dumped around 15 million shares today due to the Clear Data having lackluster results. This was Esperions big weekend where they would be able to pound their chest and it didn't happen. The market reacted accordingly today.
Click to expand...
Please, Karens, help. What is stated on page 7 of your business plans? What is the LRS? Surely you can help with the trends of NBRx softness? Please!!!!!!!!!!
 








anonymous said:
Again avoiding the question with a lackey response. Kinda of like Wall Streets reaction today of Esperion.
Click to expand...
You all are the finance, regulatory, heor, and marketing geniuses, Karens. Please! We need your circumvention skills. Page 9? What's in there? We're sorry. We should not have doubted the depths of your loser depravity. You all are the The Phoenices!
 












anonymous said:
Still no clinical discussion? Here's a chance to tell us why investors dumped around 15 million shares today due to the Clear Data having lackluster results. This was Esperions big weekend where they would be able to pound their chest and it didn't happen. The market reacted accordingly today.
Click to expand...

There will never be a Clinical discussion, because there is nothing to discuss Clinically !
CLEARS is a giant whiff !
 




Yes this didn't end up good. This will be a small market drug with a slight niche. The trial showed some benefit but not enough to make doctors think differently or Wall St either. 15-20% is the magic number. 13 % is not going to do it. Also there's not enough reps in the footprint to move market share anyways.
 




The market has been tough on high tech biosciences of late. Clearly, there was an overreaction, which creates a real unique buying opportunity. Look for significant upside over the next three months as the consolidation is in. Outcomes data is good to have, we will continue to leverage our strength ‘s and expertise.
 




Hogwash! Significant upside! What a crock. Same ludicrous post every week. What was the upside when stock went from 78.00 to 5.00 in 3 years. Esperion down 80% in two years. Market doesn't believe in Esperion as evident of markets reaction to Notso Clear data. Another failure chocked up to Esperion management.
 




Top Bottom
Back
Quote